Insilico Medicine, a clinical-stage AI-driven drug development company listed on the Hong Kong Stock Exchange under the ticker symbol 3696,...
-
-
Recent Updates
- Suspected China APT Behind VMware Exploitation: Cybersecurity Recap
- US Urges Countries to Choose Between Pax Silica and Beijing’s AI Framework
- Insilico Medicine Included in MSCI Global Small Cap Index, Recognized for Core Strengths in Capital Markets
- CATL Achieves Core Operation Carbon Neutrality, Launches Industry-Leading Carbon Neutrality Action
- United States Urges Countries to Choose Sides in Global AI Race Amid China’s Growing Influence
- China’s Self-Driving Advances in Europe: Momenta and Pony.ai Expand Reach
- CXMT’s Emergence as China’s Most Valuable Company Marks Shift in Tech Landscape
- Alibaba’s Strategic Shift: Selling Lingxi Games Arm to Fuel AI Ambitions
- China’s Challenge Faces US Alliance in AI Dominance Battle
- Changan’s Expansion Plans and Deepal’s Status in Australia
Blogroll